Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection

Introduction: Etravirine is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) specifically designed to suppress the replication of viruses resistant to the three currently approved NNRTIs efavirenz, nevirapine, and delavirdine. Aims: To assess the evidence for the place of etravirine in the treatment of HIV-1 infection. Evidence review: In combination with a ritonavir-boosted protease inhibitor etravirine has demonstrated high antiviral activity against strains exhibiting up to three NNRTI resistance mutations. The drug appears to be well tolerated, with only nausea and rash occuring significantly more frequently with etravirine compared with placebo. Of note, neuropsychologic side effects that frequently limit the use of efavirenz were not reported more frequently with etravirine. Place in therapy: Given its high activity against most NNRTI-resistant strains and its very good tolerability, etravirine is of high value for pretreated patients with NNRTI resistance and protease inhibitor exposure. Efforts should be made to demonstrate activity in switching strategies (due to toxicity) and earlier lines of failure or in the setting of primary NNRTI resistance in order to explore the potential of the drug beyond salvage therapy.

• Publication year

  2009

• Venue

  Core Evidence

• Publication date

  2009-07-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/CE.S6009PMID 20694071PMCID 2899779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA) *†

  2010cited by this paper
• Prevalence and Risk Factors for Etravirine Resistance among Patients Failing on Non-Nucleoside Reverse Transcriptase Inhibitors

  2008cited by this paper
• Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.

  2008cited by this paper
• Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers

  2008cited by this paper
• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal

  2008cited by this paper
• Transmission of drug-resistant HIV-1 in Europe remains limited to single classes

  2008cited by this paper
• Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients

  2008cited by this paper
• Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers

  2008cited by this paper
• Updated prevalence of genotypic resistance among HIV‐1 positive patients naïve to antiretroviral therapy: a single center analysis

  2008cited by this paper
• Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.

  2008cited by this paper
• A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

  2008cited by this paper
• Class-sparing regimens for initial treatment of HIV-1 infection.

  2008cited by this paper
• Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

  2008cited by this paper
• Treatment Outcome and Cost-Effectiveness of Different Highly Active Antiretroviral Therapy Regimens in the Uk (1996–2002)

  2008cited by this paper
• European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults

  2008cited by this paper
• Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

  2008cited by this paper
• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

  2007cited by this paper
• Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients

  2007cited by this paper
• Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.

  2007cited by this paper
• Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis

  2007cited by this paper
• Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

  2007cited by this paper
• The incidence of multidrug and class resistance in HIV-1 infected patients is decreasing over time (2001-2006)

  2007cited by this paper
• Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort Study

  2007cited by this paper
• Impact of transmission of drug‐resistant HIV on the course of infection and the treatment success. Data from the German HIV‐1 Seroconverter Study

  2007cited by this paper
• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

  2007cited by this paper
• Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

  2007cited by this paper
• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  2007cited by this paper
• Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers

  2007cited by this paper
• Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey

  2007cited by this paper
• Cost-Efficacy Comparison among Three Antiretroviral Regimens in HIV- 1 Infected, Treatment-Experienced Patients

  2007cited by this paper
• Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.

  2007cited by this paper
• Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

  2007cited by this paper
• HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

  2007cited by this paper
• [Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study].

  2007cited by this paper
• The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV-Infected Adults in Côte D'Ivoire

  2007cited by this paper
• Quantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and D

  2006cited by this paper
• Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

  2006cited by this paper
• Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.

  2006cited by this paper
• Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission

  2006cited by this paper
• Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

  2006cited by this paper
• Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

  2005cited by this paper
• Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003

  2005cited by this paper
• TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments

  2005cited by this paper
• Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals

  2005cited by this paper
• Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

  2005cited by this paper
• Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

  2005cited by this paper
• TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

  2004cited by this paper
• Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

  2004cited by this paper
• Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.

  2004cited by this paper
• Declining trend in transmission of drug-resistant HIV-1 in Amsterdam

  2004cited by this paper
• The impact of the M184V substitution on drug resistance and viral fitness.

  2004cited by this paper
• The impact of the M184V substitution on drug resistance and viral fitness

  2004cited by this paper
• AIDS epidemic update December 2004.

  2004cited by this paper
• An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

  2003cited by this paper
• A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

  2003cited by this paper
• European guidelines for the clinical management and treatment of HIV-infected adults in Europe.

  2003cited by this paper
• Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen *

  2001cited by this paper
• Altered Viral Fitness of HIV‐1 Following Failure of Protease Inhibitor‐Based Therapy

  2000cited by this paper
• AIDS epidemic update: December 1999.

  2000cited by this paper
• Efavirenz: resistance and cross-resistance.

  1999cited by this paper
• Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

  1997cited by this paper
• submit your manuscript | www.dovepress.com

  year unknowncited by this paper

• Etravirine resistance mutations in HIV‐infected pregnant women

  2013cites this paper
• Population pharmacokinetics and pharmacogenetics of antiretroviral drugs

  2012cites this paper
• Etravirine

  2012cites this paper
• Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics

  2011cites this paper